CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) May 19, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 â 8, 2021.
âWe are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this yearâs ASCO, including multiple novel combinations of tislelizumab with our investigational Fc-competent anti-TIGIT-antibody ociperlimab and other therapeutic agents, and the ongoing evaluation of our next-generation BTK inhibitor zanubrutinib,â commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. âWe believe that these presentations underscore the breadth and diversity, as well as the remarkable progress and momentum, in BeiGeneâ
Published: Apr 12, 2021
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after fail
1
2Medical Records Management Division, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China;
3Intensive Care Unit, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China;
4Pharmacy Services, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China These authors contributed equally to this work
Correspondence: Dehong Huang
Department of Hematology and Oncology, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Chongqing, People’s Republic of China
Tel +86 23-65311341
Purpose: This study investigated the function and molecular mechanisms of miR-744-5p in multiple myeloma (MM).
Methods: miR-744-5p and SRY-related high-mobility-group box 12 (SOX12) expression in clinical tissues and MM cells was monitored by quantitative real-time polymerase chain reactions and Western blot. miR-744-5p expression in MM cells was regulated by transfection. Cell proliferation was researched by cell counting kit-8 as
InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.